Zeeshan Mansuri, MD, MPH

Yale New Haven School of Medicine, New Haven, Connecticut

PCC
Commentary

January 20, 2022

Patients with psychiatric disorders may be at greater risk of experiencing adverse outcomes from COVID-19. Read on to find out more.
, ,
PCC
Brief Report

October 28, 2021

In this report, the authors review the potential drug-to-drug interactions and safety of using benzodiazepines with COVID-19 antiviral drugs.
, , , et al
PCC
Case Report

March 25, 2021

Here, the authors present a unique presentation of an adolescent girl with a history of bulimia nervosa with multiple chronic episodes of voluntary purging, which were immediately followed by...
, , , et al
PCC
Letter to the Editor

February 18, 2021

In this letter to the editor, the authors reply to Kow and Hasan.
, , , et al
PCC
Commentary

July 2, 2020

In this commentary, the authors discuss the potential interactions of opioid use disorder treatments with novel COVID-19 medications.
, , , et al
PCC
Commentary

June 18, 2020

In this commentary, the authors discuss the potential interactions of ritonavir/lopinavir with psychiatric medications in the context of COVID-19.
, , , et al
PCC
Commentary

May 28, 2020

The FDA has approved remdesivir for severe COVID-19 in children and adults. This commentary reviews potential interactions of remdesivir with psychotropic medications.
, , , et al
PCC
Letter to the Editor

December 26, 2019

The authors of this letter to the editor comment on a previously published report on pimavanserin in The Primary Care Companion for CNS Disorders.
, , , et al

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe